Stifel's Paul Matteis covers earnings season and recent clinical data in biotech on Analyst Thursdays
Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, Alector, Neurocrine, and more.